These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 24058075

  • 1. Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study.
    Buysschaert I, Dubois CL, Dens J, Ormiston J, Worthley S, McClean D, Ottervanger JP, Meredith I, Uren N, Wijns W, Whitbourn R, Mehran R, Lansky AJ, Bichalska M, Meis S, Verheye S.
    EuroIntervention; 2013 Sep; 9(5):573-81. PubMed ID: 24058075
    [Abstract] [Full Text] [Related]

  • 2. 9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study.
    Verheye S, Agostoni P, Dubois CL, Dens J, Ormiston J, Worthley S, Trauthen B, Hasegawa T, Koo BK, Fitzgerald PJ, Mehran R, Lansky AJ.
    J Am Coll Cardiol; 2009 Mar 24; 53(12):1031-9. PubMed ID: 19298915
    [Abstract] [Full Text] [Related]

  • 3. Impact of side branch stenting on five-year long-term clinical outcome with the bifurcation-dedicated Axxess Biolimus A9-eluting stent system.
    Verheye S, Buysschaert I, Grube E.
    EuroIntervention; 2015 Dec 24; 11(8):860-7. PubMed ID: 26696454
    [Abstract] [Full Text] [Related]

  • 4. Long-term outcomes after percutaneous revascularization of complex coronary bifurcation lesions using a dedicated self-expanding biolimus-eluting stent system.
    Triantafyllis AS, Bennett J, Pagourelias E, McCutcheon K, Adriaenssens T, Sinnaeve PR, Desmet W, Dubois C.
    Cardiol J; 2018 Dec 24; 25(4):470-478. PubMed ID: 29240962
    [Abstract] [Full Text] [Related]

  • 5. Comparative Case-Control analysis of a dedicated self-expanding Biolimus A9-eluting Bifurcation stent versus provisional or mandatory side branch intervention strategies in the treatment of coronary bifurcation lesions.
    Ohlow MA, Farah A, Richter S, El-Garhy M, von Korn H, Lauer B.
    Catheter Cardiovasc Interv; 2017 Jul 24; 90(1):39-47. PubMed ID: 27651317
    [Abstract] [Full Text] [Related]

  • 6. 5-Year clinical follow-up of the COBRA (complex coronary bifurcation lesions: Randomized comparison of a strategy using a dedicated self-expanding biolimus A9-eluting stent vs. a culotte strategy using everolimus-eluting stents) study.
    Bennett J, Adriaenssens T, McCutcheon K, Dens J, Desmet W, Sinnaeve P, Vrolix M, Dubois C.
    Catheter Cardiovasc Interv; 2018 Nov 15; 92(6):E375-E380. PubMed ID: 29536609
    [Abstract] [Full Text] [Related]

  • 7. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, Rademaker-Havinga T, van Es GA, Meier B, Jüni P, Windecker S.
    JACC Cardiovasc Interv; 2013 Aug 15; 6(8):777-89. PubMed ID: 23968698
    [Abstract] [Full Text] [Related]

  • 8. Baseline and 9 months IVUS analysis of the bifurcation-dedicated biolimus A9-eluting Axxess stent system: the DIVERGE IVUS substudy.
    Buysschaert I, Sanidas E, Hasegawa T, Koo BK, Honda Y, Fitzgerald PJ, Verheye S.
    Catheter Cardiovasc Interv; 2014 Dec 01; 84(7):1062-70. PubMed ID: 24478226
    [Abstract] [Full Text] [Related]

  • 9. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H, Kirtane AJ, Newman W, Sanz M, Hermiller JB, Mahaffey KW, Cutlip DE, Sudhir K, Hou L, Koo K, Stone GW.
    JACC Cardiovasc Interv; 2013 Dec 01; 6(12):1263-6. PubMed ID: 24239202
    [Abstract] [Full Text] [Related]

  • 10. The three year follow-up of the randomised "all-comers" trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS).
    Wykrzykowska J, Serruys P, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, Di Mario C, Van Geuns RJ, Van Es GA, Juni P, Windecker S.
    EuroIntervention; 2011 Nov 01; 7(7):789-95. PubMed ID: 22027687
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Analysis of bifurcation lesions treated with novel drug-eluting dedicated bifurcation stent system: intravascular ultrasound results of the AXXESS PLUS trial.
    Miyazawa A, Ako J, Hassan A, Hasegawa T, Abizaid A, Verheye S, McClean D, Neumann FJ, Grube E, Honda Y, Fitzgerald PJ.
    Catheter Cardiovasc Interv; 2007 Dec 01; 70(7):952-7. PubMed ID: 18044777
    [Abstract] [Full Text] [Related]

  • 13. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW.
    JACC Cardiovasc Interv; 2013 Sep 01; 6(9):914-22. PubMed ID: 24050859
    [Abstract] [Full Text] [Related]

  • 14. Clinical outcome after crush versus culotte stenting of coronary artery bifurcation lesions: the Nordic Stent Technique Study 36-month follow-up results.
    Kervinen K, Niemelä M, Romppanen H, Erglis A, Kumsars I, Maeng M, Holm NR, Lassen JF, Gunnes P, Stavnes S, Jensen JS, Galløe A, Narbute I, Sondore D, Christiansen EH, Ravkilde J, Steigen TK, Mannsverk J, Thayssen P, Hansen KN, Helqvist S, Vikman S, Wiseth R, Aarøe J, Jokelainen J, Thuesen L, Nordic PCI Study Group.
    JACC Cardiovasc Interv; 2013 Nov 01; 6(11):1160-5. PubMed ID: 24262616
    [Abstract] [Full Text] [Related]

  • 15. Comparison of abluminal biodegradable polymer biolimus-eluting stents and durable polymer everolimus-eluting stents in the treatment of coronary bifurcations.
    Costopoulos C, Latib A, Naganuma T, Sticchi A, Ferrarello S, Regazzoli D, Chieffo A, Figini F, Carlino M, Montorfano M, Naim C, Kawaguchi M, Gerasimou A, Giannini F, Godino C, Colombo A.
    Catheter Cardiovasc Interv; 2014 May 01; 83(6):889-95. PubMed ID: 23804318
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Impact of the complexity of bifurcation lesions treated with drug-eluting stents: the DEFINITION study (Definitions and impact of complEx biFurcation lesIons on clinical outcomes after percutaNeous coronary IntervenTIOn using drug-eluting steNts).
    Chen SL, Sheiban I, Xu B, Jepson N, Paiboon C, Zhang JJ, Ye F, Sansoto T, Kwan TW, Lee M, Han YL, Lv SZ, Wen SY, Zhang Q, Wang HC, Jiang TM, Wang Y, Chen LL, Tian NL, Cao F, Qiu CG, Zhang YJ, Leon MB.
    JACC Cardiovasc Interv; 2014 Nov 01; 7(11):1266-76. PubMed ID: 25326748
    [Abstract] [Full Text] [Related]

  • 18. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial.
    Silber S, Windecker S, Vranckx P, Serruys PW, RESOLUTE All Comers investigators.
    Lancet; 2011 Apr 09; 377(9773):1241-7. PubMed ID: 21459430
    [Abstract] [Full Text] [Related]

  • 19. Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial.
    Onuma Y, Miquel-Hebert K, Serruys PW, SPIRIT II Investigators.
    EuroIntervention; 2013 Jan 22; 8(9):1047-51. PubMed ID: 23339811
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.